When would you consider reusing a prior agent to treat relapsed multiple myeloma?

For instance, if a patient experienced a late relapse after autologous transplant, would you consider using regimens the patient had previously responded to during induction? Are there particular drugs or circumstances where it is feasible to include previously utilized agents in novel combination regimens?